Kommentar zu „NASH mit Leberzirrhose: Resmetirom sicher und wirksam?“

• Literatur

• 1 Rinella ME, Lazarus JV, Ratziu V. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Journal of hepatology 2023; 79: 1542-1556
• 2 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L. et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; 149: 367-378.e365
• 3 Verrastro O, Panunzi S, Castagneto-Gissey L. et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet 2023; 401: 1786-1797
• 4 Loomba R, Abdelmalek MF, Armstrong MJ. et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. The lancet Gastroenterology & hepatology 2023; 8: 511-522
• 5 Cusi K. Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH. The New England journal of medicine 2024; 390: 559-561